About the Company
oral integrin therapies for patients with immunological, fibrotic, neoplastic and vascular diseases. morphic tx is joining a three decade quest led by our scientific founder, tim springer, who initially discovered the integrin receptor family in the 1980s. this receptor family is an important drug target that has fueled the successful development of six injectable therapies approved for treatment of multiple sclerosis, ulcerative colitis, crohn's disease, plaque psoriasis, acute coronary syndrome and complications during percutaneous coronary intervention. despite blockbuster commercial success, integrins have remained out of reach as small molecule drugs...until now.
Exchange
NASDAQ
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $MORF News
Morphic Holding: Strong Financials and Promising Clinical Trials Reinforce Buy Rating
Canaccord Genuity analyst Edward Nash maintained a Buy rating on Morphic Holding (MORF – Research Report) yesterday and set a price ...
Morphic Holding Inc MORF
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Wall Street Analysts See a 56.18% Upside in Morphic Holding, Inc. (MORF): Can the Stock Really Move This High?
Morphic Holding, Inc. (MORF) closed the last trading session at $35.30, gaining 16.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets ...
Morphic Holding’s Buy Rating Affirmed on Strong Clinical and Financial Prospects
Morphic Holding (MORF) Company Description: Morphic Holding, Inc. operates as a biopharmaceutical company, which engages in the research and development of oral small-molecule integrin therapeutics.
MORF Jul 2024 17.500 put
The average of price targets set by Wall Street analysts indicates a potential upside of 56.2% in Morphic Holding, Inc. (MORF). While the effectiveness of this highly sought-after metric is ...
Wall Street Analysts Think Morphic Holding, Inc. (MORF) Could Surge 57.22%: Read This Before Placing a Bet
Morphic Holding, Inc. (MORF) closed the last trading session at $36.82, gaining 27% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set ...
Morphic Holding Stock (NASDAQ:MORF), Quotes and News Summary
Since Friday, Morphic Therapeutic (NASDAQ ... Moving In Monday's Mid-Day Session Gainers TransCode Therapeutics, Inc. (NASDAQ: RNAZ) shares jumped 308% to $2.71 after the company announced ...
New Strong Buy Stocks for February 14th
Lumen Technologies, Inc. price-consensus-chart | Lumen Technologies, Inc. Quote Morphic Holding, Inc. MORF: This biopharmaceutical company has seen the Zacks Consensus Estimate for its current ...
Morphic Holding Inc MORF
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Morphic Holding Inc (MORF)
On Wednesday, Jefferies showed increased confidence in Morphic Therapeutic (NASDAQ:MORF) by raising the company's price target from $45.00 to $60.00. The firm maintained a Buy ...
Morphic Holding Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Loading the latest forecasts...